While the two active immunotherapies generated robust titres against pathological Tau species, ACI-35.030 showed an earlier antibody response more specifically directed against phosphorylated Tau species compared to non-phosphorylated Tau, and a sustained and stable response against ePHF, which represents the endogenous pathological Tau in AD pathology. Here, MAPT is linked to Alzheimer disease.